United Therapeutics Officer Paul Mahon Files Form 144 to Sell $4.52M in Common Stock Under 10b5-1 Plan
UNITED THERAPEUTICS Corp
Subscribe to track UTHR
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
# Form 144 Notice: United Therapeutics Corp ($UTHR)
**Insider:** Paul Mahon (Officer)
**Transaction:** Proposed Sale of 8,300 Common Shares
**Total Market Value:** $4,517,709.09 (~$544.30/share)
**Broker:** Morgan Stanley Smith Barney LLC
**Acquisition:** Stock Option Exercise (Cash, 10/15/2026)
**Trading Plan:** Rule 10b5-1 adopted on 08/11/2025
**Significance:** Low (Routine scheduled 10b5-1 liquidation)
Comprehensive Analysis
Transaction Overview
On October 15, 2026, Paul Mahon, an Officer of United Therapeutics Corp ($UTHR), filed a Form 144 notice of proposed sale covering 8,300 shares of common stock. The aggregate market value of the shares proposed to be sold is approximately $4.52 million ($544.30 per share).
Acquisition and Trading Context
- Nature of Acquisition: The 8,300 shares are being acquired on October 15, 2026, through a stock option exercise paid in cash.
- Pre-Scheduled Plan: The proposed sale is executed pursuant to a Rule 10b5-1 trading plan adopted on August 11, 2025.
- Historical Activity: The filer has consistently sold 8,300 shares roughly every two weeks over the preceding three months (sales occurring on 07/16, 08/06, 08/20, 09/03, 09/17, and 10/01/2026), generating between $4.00M and $4.69M per transaction.
Market Impact & Significance
The filing represents a negligible percentage (0.019%) of United Therapeutics' 42,890,692 outstanding shares. Given the consistent cadence and adherence to a long-established Rule 10b5-1 trading plan adopted over a year prior, this filing reflects programmatic option monetization rather than a discretionary sentiment-driven shift, carrying low market significance.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.